Analysis & Insights
Watch our on demand webinar on: Weight of the world: are anti-obesity therapeutics transforming the global health landscape for good
More from Airfinity
Wegovy costs $1.3m to prevent one heart attack, stroke, or cardiovascular death
Anti-obesity drug rush: Industry 'testing' nearly 190 candidates (es)
Weight loss injections could prevent 300,000 heart failures in the US by 2030, forecasts Airfinity
Airfinity forecasts the severely obese population with metabolic syndrome in the US to grow 50% by 2030 from 26 million to 39.1 million people.
View All →
What our users say?
“Airfinity has again and again shown they can provide very accurate and actionable predictions for disease trajectories. That’s why their analytics became an essential tool for me and the White House when leading outbreak responses such as COVID-19, mpox, Marburg Virus Disease and Avian Flu.”
Nikki Romanik, Former Special Assistant to the President, Deputy Director and Chief of Staff,
Office of Pandemic Preparedness and Response Policy, White House
In a dynamic environment, Airfinity enabled us to remain on track with daily developments to enable more accurate decision-making. Airfinity combines nimbleness of real time data and their group of scientists that can analyse, model and provide strategic analysis for critical decision making.”
Iskra Reic, Executive Vice-President
Astrazeneca
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Probably the most expansive, accurate and helpful of the multiple data sets on an international scale”
Sir John Bell ,
University of Oxford